General description
INN
Metronidazole
Medicine type
Chemical agent
Antibiotic groups
EML status history
First added in 1977
(TRS
615)
for
Amoebiasis
Added in 1979
(TRS
641)
for
Bacterial infection of unspecified site
Added in 2017
(TRS
1006)
for
Peritoneal abscess
Added in 2017
(TRS
1006)
for
Peritonitis
Removed in 2017
(TRS
1006)
for
Bacterial infection of unspecified site
Added in 2017
(TRS
1006)
for
Intestinal infections due to Clostridioides difficile
Added in 2017
(TRS
1006)
for
Trichomoniasis
Added in 2019
(TRS
1021)
for
Other specified prophylactic measures
Added in 2021
(TRS
1035)
for
Necrotising fasciitis
Wikipedia
DrugBank
Recommendations
Section
Access group antibiotics
- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
Indications
First choice
Intestinal infections due to Clostridioides difficile Trichomoniasis co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with ceftriaxone Necrotising fasciitis co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe)Second choice
co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) co-prescribed with ciprofloxacin Peritonitis (mild-moderate)
Other indications
Section
Antiamoebic and antigiardiasis medicines
- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
Indications